The prediction of nonresponse to pharmacotherapy in panic disorder: A review

Depression and Anxiety

Volumn 14, Issue 2, 2001, Pages 112-122

  Slaap, Bernhard R ^a   Den Boer, Johan A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Panic disorder; Pharmacotherapy; Prediction of response

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BROFAROMINE; CLOMIPRAMINE; CLONAZEPAM; FLUVOXAMINE; IMIPRAMINE;

AGORAPHOBIA; ANXIETY; AVOIDANCE BEHAVIOR; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; ONSET AGE; PANIC; PERSONALITY; PERSONALITY DISORDER; PHOBIA; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; COMORBIDITY; DEPRESSIVE DISORDER; FOLLOW-UP STUDIES; HUMANS; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; TREATMENT FAILURE;

EID: 0034796330     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.1053     Document Type: Review

References (10)

1. Outcome of panic disorder with or without concomitant depression: A 2-year prospective follow-up study
2. Panic disorder with or without concomitant depression 5 years after treatment: A prospective follow-up
3. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: A Scandinavian multicenter study
4. Alprazolam in panic disorder and agoraphobia: Results of a multi-center trial. I. Efficacy in short term treatment
5. Assessing the efficacy of treatments for panic disorder and agoraphobia. 1. Methodological problems
6. What treatments do patients with panic disorder and agoraphobia get?
7. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure
8. Scales for assessment of diagnosis and severity of mental disorders
9. The assessment of panic using self-report: A comprehensive survey of validated instruments
10. Comorbidity among anxiety disor-